Tesamorelin | Peptide Encyclopedia | Auryx
Tesamorelin is a physician-reviewed Auryx Learn encyclopedia entry. An extensively studied GHRH analogue researched for its effects on visceral adipose tissue and IGF-1 signaling. This page is educational. It is not a dosing guide and not a substitute for a licensed clinician.
How it works
Tesamorelin is a stabilized GHRH analogue that potently stimulates pituitary GH secretion, leading to IGF-1 elevation. Its clinical distinction is a documented, statistically significant reduction in visceral abdominal fat — the metabolically dangerous fat surrounding organs — even independent of dietary changes.
- Visceral adipose tissue reduction studied in clinical research
- IGF-1 signaling elevation and anabolic pathway research
- Body composition effects studied in multiple trial contexts
- Metabolic parameter improvements in research settings
Preferred for clients with excess visceral fat, metabolic syndrome risk, or those seeking targeted abdominal body recomposition.
Originally studied in the context of lipodystrophy-associated visceral adiposity. Extensively studied in non-disease populations for its effects on the IGF-1 axis and adipose tissue dynamics.
Clinic context and next steps
Pair this entry with the matching shop listing when Auryx offers the compound, or browse the full encyclopedia. Category shopping lives under shop. Mechanism language is not a personal outcome and does not approve a protocol.
Auryx is an MD-led telemedicine clinic. Eligible patients complete remote intake; compounds ship from regulated United States compounding pharmacies after clinical review. Use the protocol finder if you are matching a goal, our method for the four-step process, and about for physician leadership. Citations sit on sources. Questions go to contact or info@auryxlife.com.
Nothing on Learn diagnoses, treats, cures, or prevents disease. Read privacy and terms before you share health information. Language homepages: español and português.